Nephrocare Health Services Limited Makes Strong Debut with 6.89% Premium, Lists at ₹491.70 Against Outstanding Subscription

Nephrocare Health Services Limited, incorporated in 2010 providing end-to-end dialysis care through wide network of 519 clinics including 51 across Philippines, Uzbekistan, and Nepal operating world's largest dialysis clinic in Uzbekistan with presence across 288 cities in 21 states and four union territories in India with approximately 77.53% clinics located in tier-two and tier-three cities addressing critical need in underserved regions serving 29,281 patients and completing 2,885,450 dialysis treatments accounting for roughly 10% of India's total dialysis patient base with 5,562 dialysis machines, made a strong debut on BSE and NSE on December 17, 2025. After closing its IPO bidding between December 10-12, 2025, the company commenced trading with a premium of 6.89% opening at ₹491.70 and touched ₹498.70 (up 8.41%).

Nephrocare Health Services Limited Listing Details

Nephrocare Health Services launched its IPO at ₹460 per share with minimum investment of 32 shares costing ₹14,720. The IPO received strong response with subscription of 14.08 times - retail investors at 2.36 times, QIB at 26.82 times, NII at 24.77 times.

First-Day Trading Performance

Listing Price: Nephrocare Health Services opened at ₹491.70 representing premium of 6.89% from issue price of ₹460.00, touched high of ₹498.70 (up 8.41%) and low of ₹476.50 (up 3.59%), with VWAP at ₹490.39, reflecting positive market sentiment with solid listing gains supported by strong subscription of 14.08 times despite aggressive valuation with post-issue P/E of 162.19x.

Growth Drivers and Challenges

Growth Drivers:

Market Leadership: India's and Asia's largest dialysis chain with fifth largest global positioning, operated 519 clinics serving approximately 10% of India's total dialysis patient base, world's largest dialysis clinic in Uzbekistan demonstrating operational scale and expertise.

Strong Growth Trajectory: Revenue increased 34% and PAT surged 91% between FY24 and FY25, ROE of 13.45%, ROCE of 18.67%, RoNW of 13.19%, PAT margin of 8.88%, strong EBITDA margin of 22.05%, track record of sustainable growth, profitability, and return.

Challenges:

Extreme Valuation: Post-issue P/E of 162.19x representing one of highest valuations despite healthcare sector positioning, issue appears aggressively priced according to analyst review, price-to-book of 7.72x.
Profitability Pressures: Higher finance costs dented bottom line for H1-FY26 performance with PAT of ₹14.23 crore for six months versus ₹67.10 crore full year FY25, company reported loss of ₹11.79 crore in FY23 before turnaround.

Utilisation of IPO Proceeds

Expansion: ₹129.11 crore for capital expenditure for opening new dialysis clinics in India expanding network beyond current 468 Indian clinics and penetrating deeper into tier-two and tier-three cities.

Debt Repayment: ₹136.00 crore for prepayment or scheduled repayment of certain borrowings strengthening balance sheet and reducing interest burden to improve financial flexibility.

General Corporate Purposes: ₹60.05 crore allocated for general corporate purposes supporting operational needs, working capital, and strategic initiatives to maintain market leadership positioning.

Financial Performance

Revenue: ₹769.92 crore for FY25, growth of 34% from ₹574.72 crore in FY24, reflecting expanding network of 519 clinics serving 29,281 patients and completing 2,885,450 dialysis treatments accounting for 10% of India's dialysis market.

Net Profit: ₹67.10 crore in FY25, impressive growth of 91% from ₹35.13 crore in FY24, representing turnaround from loss of ₹11.79 crore in FY23 demonstrating business model profitability though H1-FY26 performance of ₹14.23 crore raises sustainability concerns.

Financial Metrics: ROE of 13.45%, ROCE of 18.67%, RoNW of 13.19%, PAT margin of 8.88%, strong EBITDA margin of 22.05%, price-to-book of 7.72x, post-issue EPS of ₹2.84, extreme P/E of 162.19x, net worth of ₹594.21 crore, total borrowings of ₹225.80 crore, and market capitalisation of ₹4,790.77 crore representing India's and Asia's largest dialysis chain with strong listing premium of 6.89% despite aggressive valuation concerns.